- Home
- PFL vs ACRS Comparison
PFL vs ACRS Comparison
Compare PFL & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PFL | ACRS |
|---|---|---|
| Founded | 2003 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 371.7M | 311.0M |
| IPO Year | 2003 | 2015 |
Fundamental Metrics
Financial Performance| Metric | PFL | ACRS |
|---|---|---|
| Price | $7.99 | $4.21 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $9.75 |
| AVG Volume (30 Days) | 276.9K | ★ 2.5M |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | ★ 11.53% | N/A |
| EPS Growth | N/A | ★ 69.01 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,683,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $4.24 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.11 | $1.05 |
| 52 Week High | $8.70 | $4.89 |
Technical Indicators
Market Signals| Indicator | PFL | ACRS |
|---|---|---|
| Relative Strength Index (RSI) | 45.78 | 66.39 |
| Support Level | N/A | $2.67 |
| Resistance Level | $8.49 | $4.89 |
| Average True Range (ATR) | 0.13 | 0.26 |
| MACD | 0.02 | 0.05 |
| Stochastic Oscillator | 67.31 | 98.04 |
Price Performance
Historical ComparisonAbout PFL PIMCO Income Strategy Fund Shares of Beneficial Interest
PIMCO Income Strategy Fund is a United States-based closed-end management investment company. The fund's investment objective is to seek high current income, consistent with the preservation of capital. The company seeks to achieve its objectives by investing in a diversified portfolio of floating and fixed-rate debt instruments.
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.